Dexter’s Story: A Pet Parent’s Perspective
Meet Dexter, a lovable mixed-breed pup who’s been on a journey of resilience and love since his cancer diagnosis five years ago. His story, as told by his dedicated pet parent, shows how choosing the right care—and a little extra love—can make all the difference. With the support of FidoCure and his healthcare team, Dexter’s […]
Data-First Pet Healthcare: How FidoCure is Leveraging Big Data to Improve Canine Cancer Outcomes
In the fight against canine cancer, one of the most powerful tools at medicine’s disposal is data. Data can help describe genomes, uncover patterns in care and outcomes, and map effective drug development methodologies. But historically, collecting and making sense of all this data has been an arduous challenge, stunting advancement. At the intersection of […]
The Future of Pet Oncology: How AI-Driven Targeted Therapies are Revolutionizing Cancer Treatment for Dogs
The global veterinary oncology market has been experiencing remarkable growth, reaching a valuation of $259.4B in 2023. This surge reflects a significant shift in how pet parents approach cancer treatment for their beloved companions. Several factors are driving this expansion: increasing pet ownership rates (accelerated by the COVID-19 pandemic), a cultural shift in viewing pets […]
Global Impact from the U.S. to Korea at FAVA 2024
We are excited to share that Dr. Lucas Rodrigues, FidoCure’s Head of Veterinary Research, will be presenting twice at the 23rd Federation of Asian Veterinary Associations (FAVA) Congress, taking place from October 25 to October 27, 2024. This event marks an important opportunity for us to engage with veterinary professionals from around the world and […]
What are Gastrointestinal Cancers?
Gastrointestinal (GI) tumors in dogs are relatively rare but can be serious when they occur. These tumors affect the stomach, intestines, or other parts of the digestive system, and they can include various types such as gastrointestinal carcinomas, gastrointestinal stromal tumors (GIST), and leiomyosarcoma. While these tumors may cause symptoms like vomiting, weight loss, or […]
FidoCure To Unveil Breakthrough in Canine Hemangiosarcoma at 2024 Veterinary Cancer Society Annual Conference
PALO ALTO, Calif. (October 15, 2024) — FidoCure, a leader in AI-driven precision oncology for dogs, is excited to share landmark findings at the 2024 Veterinary Cancer Society (VCS) Annual Conference. This research, Genetic Alterations Associated with Prognosis and Better Therapeutic Outcomes in Dogs with Splenic Hemangiosarcoma, marks a significant advancement in the fight against hemangiosarcoma, […]
Pancreatic Cancer in Dogs
Pancreatic cancer, though rare, is a serious condition in dogs, with two of the most common forms being insulinoma and pancreatic adenocarcinoma. These tumors can be life-threatening, but early detection and specialized care, including emerging treatments like targeted therapies, offer new hope for affected dogs.
What to Know About Anal Sac Carcinoma
Anal sac carcinoma is a highly aggressive cancer that develops in the small glandular structures on either side of a dog’s anus. These sacs produce a strong-smelling substance that dogs use as a territorial scent marker, among other reasons. Normally, this substance is released during defecation or when a dog is nervous or excited. However, […]
FidoCure Leads Canine Cancer Research with the World’s Largest Canine Cancer Database
At FidoCure, we’re committed to transforming cancer care for dogs through precision medicine. Our journey began with a mission to address a critical gap in canine cancer research and treatment. Prior to 2019, the field of canine cancer genomics lagged significantly behind its human counterpart. With only 2,000 canine tumor samples sequenced worldwide (compared to […]
FidoCure Celebrates National Veterinary Technician Week
As National Veterinary Technician Week (October 13-19) approaches, FidoCure is proud to celebrate the vital role vet techs play in supporting pets and their families in the fight against cancer.